Nuvectis in-licenses late-stage oncology drugs and raises $115M in follow-on offering to fund pipeline expansion

Nuvectis acquired ex-China rights to oncology assets NXP100 and NXP200 and closed a $115M July 2026 follow-on offering with cash runway extending into 1H 2029.